

Rosuvastatin for primary and secondary prevention of cardiovascular disease

NHS Devon

Commissioning policy

The routine commissioning of rosuvastatin for primary and secondary prevention of cardiovascular disease is accepted in Devon for patients who are intolerant of other appropriate statins. The Formulary Interface Group should include this in locally defined treatment recommendations.

Rationale for the decision

National Institute for Health and Care Excellence (NICE) Clinical Guideline 181 recommends high intensity statins for the primary and secondary prevention of cardiovascular disease. The routine commissioning of rosuvastatin enables cholesterol to be managed in line with NICE CG181 offering an additional treatment option for patients who are intolerant of other appropriate statins.

Guidance notes on exceptionality

This general policy does not replace clinical judgement on the appropriate treatment of an individual patient.

Date of publication:	Version:
01.02.2021	Policy agreed by NHS Devon CCG
	Policy adopted by NHS Devon ICB on 01.07.2022